Related Experiment Videos
AN-1792 (Elan)
1Seth GS Medical College, Department of Pharmacology and Therapeutics, Parel, Mumbai, India. mthatte@bom5.vsnl.net.in
Current Opinion in Investigational Drugs (London, England : 2000)
|September 25, 2001
Summary
Elan is developing AN-1792, an immunotherapy for Alzheimer's disease (AD), targeting beta-amyloid. Clinical trials are progressing, with potential regulatory filings and market launch anticipated in the coming years.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
- Current treatments for AD are limited, necessitating novel therapeutic approaches.
- Beta-amyloid peptide accumulation is a key pathological hallmark of AD.
Purpose of the Study:
- To evaluate AN-1792, a potential immunotherapy for Alzheimer's disease.
- To advance the development of anti-beta-amyloid therapies.
Main Methods:
- AN-1792 is undergoing Phase I clinical trials.
- Phase II/III trials are planned to commence in the US and UK.
- Collaborations are in place for research and development, including antibody investigation.
Main Results:
- The clinical program for AN-1792 is projected to span approximately four years.
- Financial analysts have provided timelines for potential pivotal trial entry and New Drug Application (NDA) filings.
Conclusions:
- AN-1792 represents a promising immunotherapy candidate for Alzheimer's disease.
- Successful completion of ongoing and planned clinical trials is critical for regulatory approval and market availability.